Richard D Francis bought stock once, on Nov 17, 2017

Richard D. Francis is a seasoned pharmaceutical executive and the President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. (TEVA), where he also serves as a member of the Board of Directors.( He was appointed President and CEO effective January 1, 2023, bringing to Teva nearly three decades of experience in the global life sciences, biologics, and generics sectors and a track record of leading large, complex organizations through strategy shifts and growth initiatives.(

Before joining Teva, Francis was an Operating Partner at Syncona and CEO of two of its portfolio companies, Purespring Therapeutics and Forcefield Therapeutics, focusing on innovative gene and cardiovascular therapies.( From 2014 to 2019, he served as Chief Executive Officer of Sandoz and was a member of the Novartis Executive Team, following a 13-year tenure at Biogen, where he held senior commercial roles and led the successful U.S. launch of Tecfidera® for multiple sclerosis.( Francis has also served on the Board of Directors of Mettler-Toledo International Inc. and holds a Bachelor of Arts in Economics from Manchester Metropolitan University.(

Written by Perplexity from public sources.